Aperta Biosciences
Emerging biopharma company focused on discovery and development of therapeutics for ocular surface disease, particularly blepharitis and related conditions. The organization develops ophthalmic formulations including a patent-pending ophthalmic suspension that is a reformulation of an active pharmaceutical ingredient previously approved by the FDA. Leadership includes executives with operational and regulatory experience in ophthalmic drug development.
Industries
biotechnology
life-science
pharmaceutical
Aperta Biosciences
Saint Louis, Missouri, United States, North America
Products
APT-001
Patent-pending ophthalmic suspension that is a reformulation of an active pharmaceutical ingredient previously approved by the FDA; described as a mechanism that directly targets and eradicates ocular demodicosis associated with blepharitis.
APT-001
Patent-pending ophthalmic suspension that is a reformulation of an active pharmaceutical ingredient previously approved by the FDA; described as a mechanism that directly targets and eradicates ocular demodicosis associated with blepharitis.
Expertise Areas
- Ophthalmic drug development
- Topical ocular formulation and suspension development
- Drug reformulation and repurposing
- Therapeutics targeting parasitic contributors to ocular disease
Key Technologies
- Ophthalmic suspension formulations
- Topical formulation chemistry
- API reformulation
- Anti-parasitic therapeutic mechanisms for ocular use